Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Pembrolizumab Shows Intriguing Benefit in Leptomeningeal Metastasis From Solid Tumors
November 12, 2020 — Pembrolizumab led to a 38% central nervous system response rate and was well tolerated in patients with leptomeningeal metastasis from solid tumors. However, the study was closed early due to poor accrual.
Cosibelimab Elicits Early Activity in NSCLC and Cutaneous Squamous Cell Carcinoma
November 12, 2020 - The investigational PD-L1 inhibitor cosibelimab demonstrated durable and robust responses in patients with non–small cell lung cancer and cutaneous squamous cell carcinoma.
CMP-001 Plus Pembrolizumab Elicits Deep Responses, Reverses PD-1 Resistance in Advanced Melanoma
November 12th 2020November 12, 2020 - The combination of CMP-001 intratumoral injection and pembrolizumab was found to reverse PD-1 blockade resistance and elicit durable systemic responses in patients with advanced melanoma.
Cemiplimab Elicits Antitumor Activity in Metastatic Basal Cell Carcinoma
November 12th 2020November 12, 2020 - Cemiplimab demonstrated clinically meaningful antitumor activity, including durable responses, and acceptable safety in patients with metastatic basal cell carcinoma after progression on or intolerance to hedgehog inhibitors
Next-Generation Bispecific Antibody Shows Early Clinical Activity in Advanced Solid Tumors
November 12, 2020 - The first-in-class, next-generation, DuoBody-PD-L1×4-1BB bispecific antibody GEN1046 demonstrated promising early activity and an acceptable safety profile in in patients with advanced solid tumors.
Cabozantinib/Pembrolizumab Trial Poised to Improve Efficacy, Safety in Advanced Melanoma
November 12, 2020 - In an effort to further improve outcomes without sacrificing tolerability, the combination of cabozantinib with pembrolizumab is being evaluated in patients with advanced melanoma in a phase 1b/2 study.
Chemoimmunotherapy Remains Best Choice for Some PD-L1–High Lung Cancers
November 10, 2020 - Nasser Hanna, MD, discusses immunotherapy and, although, it may be the right therapy for most patients with lung cancer expressing PD-L1 greater than or equal to 50%, for those who are at risk for cancer-related morbidity with early progressive disease, chemoimmunotherapy may be the more appropriate choice.
MET, RET, and TRK Inhibitors Achieve Standard-of-Care Status in Lung Cancer
November 9th 2020Alterations in MET, RET, and NTRK have become established actionable drivers of oncogenesis in lung cancer, and therapeutics targeting these aberrations have since obtained regulatory approval from the FDA and have been incorporated into treatment guidelines.
ctDNA Shows Promise as a Potential Biomarker for MRD in Locally Advanced NSCLC
November 9th 2020Maximilian Diehn, MD, PhD, discusses how the use of circulating tumor DNA to analyze minimal residual disease status in patients with lung cancer and other solid tumors is a rapidly developing field with the potential to further personalize treatment decisions about adjuvant therapy.
Halmos Highlights Lessons Learned From the COVID-19 Crisis in Lung Cancer
The oncology community has risen up as a unified front in the battle against coronavirus disease 2019, launching pivotal research efforts to better understand the enemy and collecting data to develop effective therapeutics to fill the treatment arsenal.
TMB Shows Potential as Immunotherapy Biomarker in Lung Cancer, But Challenges Remain
Tumor mutational burden has been associated with response to immunotherapy in patients with lung cancer, but there have been various criticisms regarding the validity and routine use of this as a biomarker.
Clinical Activity, Safety of Modified Nivolumab/Ipilimumab Dose in RCC Confirm Best Practices
November 7th 2020A modified dosing schedule of frontline nivolumab (Opdivo) and ipilimumab (Yervoy) compared with the standard dose showed no differences in responses or safety in patients with advanced renal cell carcinoma, according to results of the CheckMate-920 trial.
Choosing Among First-Line IO/TKI Combos in RCC: The Affordable Option Is the Winner
November 7th 2020Combination regimens comprised of immunotherapy and TKI inhibitors have yielded significant benefits in terms of overall survival and progression-free survival with acceptable safety in patients with renal cell carcinoma; however, the cost of these regimens may negate the impact of these advances.
Management of Small Cell Lung Cancer Moves Forward With Immunotherapy
November 7th 2020Frontline chemoimmunotherapy trials represent a critical milestone in extensive-stage small cell lung cancer, but one that requires better understanding of the methods that can be used to broaden the patient population in whom durable benefit is currently concentrated.
Efforts to Target Actionable Alterations in Lung Cancer Abound, Emphasizing Need for Testing
November 7th 2020Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.
Lenvatinib/Pembrolizumab Shows Promise After PD-1/PD-L1 Inhibition in Metastatic Clear Cell RCC
The combination of lenvatinib plus pembrolizumab demonstrated encouraging antitumor activity in patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy.
.jpg?fit=crop&auto=format)
